UY39517A - Inhibidores de la btk - Google Patents
Inhibidores de la btkInfo
- Publication number
- UY39517A UY39517A UY0001039517A UY39517A UY39517A UY 39517 A UY39517 A UY 39517A UY 0001039517 A UY0001039517 A UY 0001039517A UY 39517 A UY39517 A UY 39517A UY 39517 A UY39517 A UY 39517A
- Authority
- UY
- Uruguay
- Prior art keywords
- btk inhibitors
- formula
- btk
- inhibitors
- variables
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063113515P | 2020-11-13 | 2020-11-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY39517A true UY39517A (es) | 2022-06-30 |
Family
ID=78828007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001039517A UY39517A (es) | 2020-11-13 | 2021-11-12 | Inhibidores de la btk |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20240083900A1 (https=) |
| EP (1) | EP4244223A1 (https=) |
| JP (1) | JP7839790B2 (https=) |
| KR (1) | KR20230119134A (https=) |
| CN (1) | CN116783199A (https=) |
| AR (1) | AR124048A1 (https=) |
| AU (1) | AU2021377891A1 (https=) |
| BR (1) | BR112023009116A2 (https=) |
| CL (1) | CL2023001367A1 (https=) |
| CO (1) | CO2023007677A2 (https=) |
| MX (1) | MX2023005626A (https=) |
| TW (1) | TW202233624A (https=) |
| UY (1) | UY39517A (https=) |
| WO (1) | WO2022104079A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023086575A1 (en) * | 2021-11-12 | 2023-05-19 | Biogen Ma Inc. | Btk inhibitors |
| KR20250005229A (ko) | 2022-05-04 | 2025-01-09 | 하. 룬드벡 아크티에셀스카브 | 모노아실글리세롤 리파제 억제제로서 1,1,1,3,3,3-헥사플루오로프로판-2-일 (s)-1-(피리다진-3-일카르바모일)-6 아자스피로[2.5]옥탄-6-카르복실레이트의 결정질 형태 |
| JP2025515728A (ja) * | 2022-05-10 | 2025-05-20 | バイオジェン・エムエイ・インコーポレイテッド | Ｎ－メチル－Ｎ－（（１ｓ，３ｓ）－３－メチル－３－（（６－（１－メチル－１Ｈ－ピラゾール－４－イル）ピラゾロ［１，５－ａ］ピラジン－４－イル）オキシ）シクロブチル）アクリルアミドの結晶多形 |
| WO2024083111A1 (zh) * | 2022-10-18 | 2024-04-25 | 首药控股(北京)股份有限公司 | 一种新型杂环化合物 |
| WO2024117205A1 (ja) * | 2022-11-30 | 2024-06-06 | 北興化学工業株式会社 | 双環式ピリジン誘導体およびその塩、並びに、当該誘導体又はその塩を有効成分として含有することを特徴とする有害生物防除剤 |
| CN116693357B (zh) * | 2023-06-07 | 2026-01-27 | 西安工程大学 | 一种β-三氟甲基不饱和酰胺及其合成方法 |
| WO2025049254A1 (en) * | 2023-08-25 | 2025-03-06 | Juno Therapeutics, Inc. | Pyrazolopyridine based inhibitors of dna-dependent protein kinase and compositions and application in gene editing |
| CN118955332A (zh) * | 2024-07-31 | 2024-11-15 | 德阳悦合生物医药科技有限公司 | 一种作为医药中间体的化合物叔丁基甲基(3-酮环丁基)氨基甲酸酯的制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2266908C (en) * | 1996-09-27 | 2010-07-20 | Joseph E. Saavedra | O2-arylated or o2-glycosylated 1-substituted diazen-1-ium-1,2-diolates and o2-substituted 1-[(2-carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolates |
| JP2001302667A (ja) | 2000-04-28 | 2001-10-31 | Bayer Ag | イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体 |
| CN103987713A (zh) | 2011-10-12 | 2014-08-13 | 阵列生物制药公司 | 5,7-取代的咪唑并[1,2-c]嘧啶 |
| RS58361B1 (sr) * | 2013-07-31 | 2019-03-29 | Merck Patent Gmbh | Piridini, pirimidini i pirazini, kao inhibitori btk i njihova upotreba |
| WO2015157955A1 (en) * | 2014-04-17 | 2015-10-22 | Abbvie Inc. | Heterocyclic btk inhibit ors |
| WO2020114487A1 (en) * | 2018-12-07 | 2020-06-11 | Sunshine Lake Pharma Co., Ltd. | Ret inhibitors, pharmaceutical compositions and uses thereof |
| EP3898626A1 (en) | 2018-12-19 | 2021-10-27 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases |
| JP2025515728A (ja) * | 2022-05-10 | 2025-05-20 | バイオジェン・エムエイ・インコーポレイテッド | Ｎ－メチル－Ｎ－（（１ｓ，３ｓ）－３－メチル－３－（（６－（１－メチル－１Ｈ－ピラゾール－４－イル）ピラゾロ［１，５－ａ］ピラジン－４－イル）オキシ）シクロブチル）アクリルアミドの結晶多形 |
-
2021
- 2021-11-12 EP EP21823425.0A patent/EP4244223A1/en active Pending
- 2021-11-12 AR ARP210103131A patent/AR124048A1/es unknown
- 2021-11-12 AU AU2021377891A patent/AU2021377891A1/en active Pending
- 2021-11-12 BR BR112023009116A patent/BR112023009116A2/pt unknown
- 2021-11-12 UY UY0001039517A patent/UY39517A/es unknown
- 2021-11-12 US US18/036,853 patent/US20240083900A1/en active Pending
- 2021-11-12 KR KR1020237019845A patent/KR20230119134A/ko active Pending
- 2021-11-12 CN CN202180089379.6A patent/CN116783199A/zh active Pending
- 2021-11-12 TW TW110142205A patent/TW202233624A/zh unknown
- 2021-11-12 MX MX2023005626A patent/MX2023005626A/es unknown
- 2021-11-12 WO PCT/US2021/059168 patent/WO2022104079A1/en not_active Ceased
- 2021-11-12 JP JP2023528245A patent/JP7839790B2/ja active Active
-
2023
- 2023-05-11 CL CL2023001367A patent/CL2023001367A1/es unknown
- 2023-06-13 CO CONC2023/0007677A patent/CO2023007677A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2023001367A1 (es) | 2024-01-05 |
| JP2023549360A (ja) | 2023-11-24 |
| CO2023007677A2 (es) | 2023-09-08 |
| TW202233624A (zh) | 2022-09-01 |
| BR112023009116A2 (pt) | 2023-10-03 |
| CN116783199A (zh) | 2023-09-19 |
| AR124048A1 (es) | 2023-02-08 |
| MX2023005626A (es) | 2023-07-31 |
| KR20230119134A (ko) | 2023-08-16 |
| WO2022104079A1 (en) | 2022-05-19 |
| JP7839790B2 (ja) | 2026-04-02 |
| US20240083900A1 (en) | 2024-03-14 |
| AU2021377891A1 (en) | 2023-07-06 |
| EP4244223A1 (en) | 2023-09-20 |
| AU2021377891A9 (en) | 2024-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY39517A (es) | Inhibidores de la btk | |
| CL2021001575A1 (es) | Pirazolopirimidinas sustituidas y purinas sustituidas y su uso como inhibidores de proteasa procesadora específica de ubiquitina 1 (usp1) | |
| PY2005283A (es) | Inhibidores de cdk2 | |
| ECSP21034668A (es) | Derivados de 2,3-dihidro-1h-pirrolo[3,4-c]piridin-1-ona como inhibidores de hpk1 para el tratamiento de cáncer | |
| CO2025013134A2 (es) | Inhibidores de kras | |
| CL2022000093A1 (es) | Imidazopirimidinas como inhibidores de eed y uso de estas | |
| CO2024005925A2 (es) | Moléculas pequeñas para el tratamiento del cáncer | |
| NI201900013A (es) | Inhibidor de piridopirimidinona cdk2/4/6 | |
| JOP20230277A1 (ar) | مثبطات الكرومينون الألستيرية للفوسفونوسيتيد 3-كيناز (pi3k) لعلاج الأمراض | |
| MX2022001158A (es) | Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales. | |
| UY39303A (es) | Inhibidores de mutación her2 | |
| CO2018007278A2 (es) | Derivados de ácido aminobenzoico metaazacíclico como antagonistas de la integrina pan | |
| CL2025001257A1 (es) | Proceso de elaboración de derivados de morfolinas sustituidas | |
| UY39193A (es) | Compuestos de azalactama como inhibidores de hpk1 | |
| CL2023003921A1 (es) | Inhibidores de transglutaminasas | |
| CL2025000087A1 (es) | Compuestos inhibidores de tirosina quinasa 2 y uso. | |
| MX2023015490A (es) | Inhibidores de las transglutaminasas. | |
| CL2024001524A1 (es) | Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno | |
| ECSP24007534A (es) | Inhibidores de transglutaminasas | |
| AR132890A1 (es) | Aminas bicíclicas como inhibidores de cdk2 | |
| AR122805A1 (es) | Inhibidores de mutación her2 | |
| UY40681A (es) | COMPUESTOS DE 1-H-PIRROLO[2,3-c]PIRIDINA | |
| AR131945A1 (es) | Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno | |
| PY2153042A (es) | Inhibidores de mutación her2 |